Enrichment Design : Additional Screening Process
Identification of a human subject into a study for a clinical trial involves screening and placebo run in periods. In some cases additional screening process is required as some therapeutic agents will be effective in patients with some disorders as they show changes in response. Hence, an additional screening process called Enrichment design is employed in the clinical trials which includes active treatments as it helps in easy identification of patients in whom test agents are found to be beneficial during early phase of trial. They also helps in identification of patients with better therapeutic response. Thus, this additional screening process restricts the target population into a very small selective group during the clinical trial making the trial process easier and effective.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).